Research and Development

We are advancing alicaforsen for the treatment of GI diseases. In addition renzapride offers the potential for clinical treatment of GI dysmotility.

Alicaforsen is a novel antisense oligonucleotide targeted to down regulate the production of ICAM-1, a cell surface receptor which is involved in the process of inflammation.

Renzapride is considered best in class orally bioavailable small molecule with a dual mode of action which can increase gut motility and reduce nausea and vomiting.